Redhill Biopharma Ltd (RDHL NASDAQ) stock market data APIs
$1.0221
-0.09(-8.8%)
as of June 5, 2026
Try our APIs with
free plan!
Redhill Biopharma Ltd Financial Data Overview
Price chart is built with
Anychart
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.
Prev. Close
1.0221
Open
0.9362
High
1.0558
Low
0.9254
52 wk Range
0.71-3.3099
Market Cap
5 347 K
P/E Ratio
0
Shares Outstanding
5 191 K
Revenue
286 K
EPS
0
Beta
4.972
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Redhill Biopharma Ltd data using free add-ons & libraries
Get Redhill Biopharma Ltd Fundamental Data
Redhill Biopharma Ltd Fundamental data includes:
- Net Revenue: 286 K
- EBITDA: -7 793 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-12
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Redhill Biopharma Ltd News
New
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of t...
RedHill Biopharma regains Nasdaq stockholders’ equity compliance
* RedHill Biopharma (RDHL [https://seekingalpha.com/symbol/RDHL]) has regained compliance [https://seekingalpha.com/pr/20323207-redhill-biopharma-successfully-regains-compliance-with-nasdaq-stockhold...
RedHill received Talicia licensing payments totaling $1.1 million
* RedHill Biopharma (NASDAQ:RDHL [https://seekingalpha.com/symbol/RDHL]) on Monday announced that it has received its first Talicia ex-U.S. sales milestone, royalties and other payments totaling ...
Form 6K Redhill Biopharma Ltd For: 18 August
Get Redhill Biopharma Ltd fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
